Rayonier Advanced Materials Announces Preliminary Second Quarter Results Impacted By COVID-19 With Improved Liquidity

Mativ Second Quarter 2022 Highlights (reflects legacy SWM results) •Sales increased 13% to $426.4 million; organic sales growth of 11% with strong demand and pricing actions across the business driving top-line gains and offsetting cost increases •GAAP EPS of $0.36, up from $0.06; Adjusted EPS of $0.86, down 4%; Adjusted EBITDA up 1% year-over-year and up 5% sequentially. Neenah Second Quarter 2022 Highlights (not included in Mativ results) •Net sales increased 14% to $306.8 million; organic sales growth was 17%, driven by release liners, water filtration, and industrials and broad strength across the paper and packaging portfolio •GAAP operating income was $17.0 million; Adjusted EBITDA increased 14% to $36.2 million; price increases more than offset higher input costs

International technology group ANDRITZ has successfully started up the tissue production line delivered to Xuong Giang Paper Mill, Vietnam, a subsidiary company of Bac Giang Import Export JSC. The PrimeLineCOMPACT S 1300 tissue machine has a design speed of 1,300 m/min and a paper width of 2.85 m, processing virgin pulp as raw material to produce high-quality facial and toilet tissue as well as napkins. It is equipped with a 12-ft. PrimeDry Steel Yankee – manufactured at the ANDRITZ Steel Yankee Business Center in Foshan, China – with a steam-heated hood to ensure highly efficient drying and substantial energy cost savings compared to operations with a cast-iron Yankee and gas-heated hood.

Chief Executive Officer Julie Schertell commented, "We saw meaningful increases in volume and profitability in Filtration and our overall SAS segment during the third quarter, with SAS segment adjusted EBITDA increasing almost 20% year over year. This was somewhat offset by results in Advanced Films, which were impacted by automotive and construction end markets. As such, we have launched a turnaround effort specific to Advanced Films focused on demand generation, operational performance and increased customer and end market diversification. This turnaround effort will be similar to the approach we used for Healthcare throughout 2023, which year-to-date, resulted in above-market sales growth of more than 5% and materially improved profitability versus the same period in 2023. Given the prevailing macro-economic conditions and the slow pace of demand recovery, we continue to prioritize those things that we can control and execute on actions to mitigate external market factors, such as the $20 million reduction in non-operating cost announced earlier this year. Additionally, we are increasing capacity in our growth categories of filtration, specialty tapes, release liners and medical films, while at the same time reducing cost and optimizing our supply chain by reducing our plant footprint from 48 sites at the time of the merger to 35 sites today and our warehousing footprint by more than 25%. These actions reduce cost and complexity, and support sustained margin improvements as demand returns.”